Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

目前，对于疼痛超敏（Pain hypersensitivity）的研究，已经知道它源于外周和脊髓体感神经元的可塑性变化，这些变化会改变向大脑传递的伤害性输入，进而影响疼痛感知。然而，作为传递伤害性信息到大脑的主要通路 —— 前外侧束（anterolateral tract，ALT），在不同疼痛状态下的功能组织却尚未完全明确。以往对 ALT ...

The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...